VTGN vs. PTI, MACK, ESPR, SLRN, FBLG, CTNM, TERN, BMEA, ORGO, and VRCA
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), Esperion Therapeutics (ESPR), Acelyrin (SLRN), FibroBiologics (FBLG), Contineum Therapeutics (CTNM), Terns Pharmaceuticals (TERN), Biomea Fusion (BMEA), Organogenesis (ORGO), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "medical" sector.
Vistagen Therapeutics (NASDAQ:VTGN) and Proteostasis Therapeutics (NASDAQ:PTI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Proteostasis Therapeutics shares are owned by institutional investors. 1.0% of Vistagen Therapeutics shares are owned by insiders. Comparatively, 4.8% of Proteostasis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Vistagen Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Proteostasis Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Proteostasis Therapeutics received 36 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote.
In the previous week, Vistagen Therapeutics had 2 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 2 mentions for Vistagen Therapeutics and 0 mentions for Proteostasis Therapeutics. Vistagen Therapeutics' average media sentiment score of 0.94 beat Proteostasis Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the media.
Proteostasis Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Vistagen Therapeutics' return on equity of -72.10% beat Proteostasis Therapeutics' return on equity.
Proteostasis Therapeutics has higher revenue and earnings than Vistagen Therapeutics.
Vistagen Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 392.23%. Given Vistagen Therapeutics' higher possible upside, equities analysts clearly believe Vistagen Therapeutics is more favorable than Proteostasis Therapeutics.
Summary
Vistagen Therapeutics beats Proteostasis Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
